ACE inhibitors as a risk factor for hypoglycemia
Abstract
It is known that hypoglycemia is associated with an increased risk of cardiovascular adverse events including death. ACE-inhibitors, when taken withantidiabetic drugs, can cause hypoglycemic episodes by improving insulin sensitivity. This clinical case illustrates the necessity to monitor plasmaglucose in the early phase of the treatment by the ACE-inhibitors in diabetic patients.
About the Authors
Andrey Alexeevich Aleksandrov
Endocrinology Research Centre, Moscow
Svetlana Semenovna Kukharenko
Endocrinology Research Centre, Moscow
Maria Nikolaevna Kulieva
Endocrinology Research Centre, Moscow
Olesya Mikhailovna Shatskaya
Endocrinology Research Centre, Moscow
Olga Alexandrovna Shatskaya
Endocrinology Research Centre, Moscow
Irina Ivanovna Mart'yanova
Endocrinology Research Centre, Moscow
Elena Nikolaevna Drozdova
Endocrinology Research Centre, Moscow
Alexandra Leonidovna Kudryashova
Endocrinology Research Centre, Moscow
References
1. Desouza C., Bolli G., Fonseca V. Hypoglycemia, Diabetes, and Cardiovascular Events // Diabetes Care. - 2010. - Vol. 33. - P. 1389-1394.
2. Graveling A., Frier B. Review: Does hypoglycaemia cause cardiovascular events? // The British Journal of Diabetes & Vascular Disease. - 2010. - Vol. 10. - Р. 5-13.
3. Yakubovich N.,Gerstein H. Serious Cardiovascular Outcomes in Diabetes: The Role of Hypoglycemia // Circulation. - 2011. - Vol. 123. - Р. 342-348.
4. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная ги- пертензия. - М.: ООО «Медицинское информационное агентство», 2006. - 344 с.
5. Gross J., Azevedo M., Silveiro S., Henrique C., Caramori M., Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment // Diabetes Care. - 2005. - Vol. 28. - P. 164-176.
6. Voulgari C., Papadogiannis D., Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies // Vascular Health and Risk Management. - 2010. - Vol. 6. - P. 883-903.
7. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) European Heart Journal Supplements. - 2007. - Vol. 9. - P. 3-74.
8. McGuire D., Winterfield J., Rytlewski J. and Ferrannini E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus // Diabetes and Vascular Disease Research. - 2008. - Vol. 5. - P. 59-66.
9. Marre M. and Leye A. Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity // Diabetes and Vascular Disease Research. - 2007. - Vol. 4. - P. 163-173.
10. Otto T. and Lane M. Adipose development: from stem cell to adipocyte // Crit. Rev. Biochem Mol Biol. - 2005. - Vol. 4. - P. 229-242.
11. Stump C., Hamilton M. and Sowers J. Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus // Mayo Clinic Proceedings. - 2006. - Vol. 6. - P. 796-806.
12. Engeli S., Schling P., Gorzelniak K., Boschmann M., Janke J., Ailhaud G., Teboul M., Massiera F. and Sharmaet A. The adipose-tissue reninangiotensin- aldosterone system: role in the metabolic syndrome? // Int. J. Biochem Cell Biol. - 2003. - Vol. 6. - P. 807-825.
13. Goossens G., Blaak E., van Baak M. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disordes // Obes. Rev. - 2003. - Vol. 4. - P. 43-55.
14. Rasouli N. and Kern P. Adipocytokines and the Metabolic Complications of Obesity // J. Clin. Endocrinol. Metab. - 2008. - Vol. 93. - P. 64-73.
Review
For citations:
Aleksandrov A.A., Kukharenko S.S., Kulieva M.N., Shatskaya O.M., Shatskaya O.A., Mart'yanova I.I., Drozdova E.N., Kudryashova A.L. ACE inhibitors as a risk factor for hypoglycemia. Diabetes mellitus. 2011;14(4):107-110. (In Russ.)
Views:
2814
Email this article 
